Acadia Pharma (NASDAQ: ACAD) reported Q3 EPS of ($0.61), $0.05 worse than the analyst estimate of ($0.56). Revenue for the quarter came in at $5.3 million versus the consensus estimate of $2.9 million.

For earnings history and earnings-related data on Acadia Pharma (ACAD) click here.